Comparative Pharmacology
Head-to-head clinical analysis: THEOLIXIR versus TORNALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOLIXIR versus TORNALATE.
THEOLIXIR vs TORNALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
None Documented
None Documented
Terminal elimination half-life is 3–5 hours in adults (nonsmokers), but prolonged to 6–8 hours in neonates, elderly, and patients with hepatic cirrhosis or heart failure. Smoking (tobacco or marijuana) reduces half-life to 1–2 hours due to enzyme induction.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; the remainder is hepatically metabolized, with 80% excreted in urine as metabolites (1-methyluric acid and 3-methylxanthine) and less than 10% in feces.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Category C
Category C
Bronchodilator
Bronchodilator